1,721,052 research outputs found
Standardization of lupus anticoagulant. The Lupus Anticoagulant Sensitivity Index (LASI)
Results for lupus anticoagulant (LA) are expressed as ratio of patient-to-normal clotting times (LA-ratio) according to the equation LA-ratio=(PatientClotting time/NormalClotting time). However, numerical results vary according to the method used for testing, thus making difficult the between-method and between-laboratory comparison of results. The hypothesis that the standardization model currently employed for the international normalized ratio for patients on warfarin is valid also for LA standardization has been taken into consideration. The model calls for the determination of a LA-sensitivity index (LASI) for each commercial method for LA detection against a common standard method. The LASI is then used to convert the LA-ratio into a scale called standardized LA-ratio (SLA-ratio) according to the equation SLA-ratio=(LA-ratio)LASI. The model proved effective in minimizing the between-method variability of results for LA detection. If implemented it could be a valuable tool to improve the comparability of results obtained in different laboratories, to quantify the LA potency and thus pave the way to the organization of collaborative clinical trials aimed at assessing whether the potency of LA is a risk factor for clinical events
More on: laboratory investigation of lupus anticoagulants: mixing studies are sometimes required
Antiphospholipid Syndrome. Laboratory Detection, Mechanisms of Action and Treatment
The antiphospholipid syndrome (APS) identifies a condition at increased risk of vascular occlusion and/or pregnancy complications. Patients are defined as having APS if they have at least one clinical (vascular occlusion and/or pregnancy complications) and one laboratory criterion at the same time. The laboratory criteria that define APS are repeated positivity (confirmed 12 weeks apart) for lupus anticoagulants and/or antibodies targeted against cardiolipin or beta(2)-glycoprotein I immobilized on solid surfaces. Over the years, APS has attracted the interest of many medical specialties. The aim of this review is to provide an update on (i) the laboratory criteria that determine the presence of APS, (ii) how the antibodies increase the risk of vascular occlusion and foetal loss and (iii) the treatment of the related clinical events
Anti phospholipid antibody ELISAs : Survey on the performance of clinical laboratories assessed by using lyophilized affinity-purifled IgG with anticardiolipin and anti-beta 2-glycoprotein I activity
Lupus anticoagulant (LA) and anticardiolipin (aCL) antibodies are the classical tests used to diagnose the antiphospholipid syndrome (APS). Unfortunately, since these are nonspecific and standardization is lacking, the results of laboratory work-ups upon which diagnosis are made are often misleading. The performance of clinical laboratories in detecting LA using lyophilised affinity purified immunoglobulin has been previously reported. The same material was used to investigate the inter-laboratory variability of aCL and anti-β2-Glycoprotein I (β2-GPI) antibody measurements. Laboratories were asked to test normal plasma spiked with purified IgG or distilled water in order to obtain 3 samples positive for aCL and anti-β2-GPI at different antibody concentration (A, B and C) and 3 samples of normal plasma. Thirty-five laboratories participated and interpreted their test results. All performed an ELISA for IgG aCL antibodies, while 17 also tested samples using IgG anti-β2-GPI antibody ELISA. Sensitivity and specificity were calculated on the basis of the responses provided by each laboratory. Overall, 99/105 samples were correctly interpreted as positive and 97/101 as negative for the presence of IgG aCL, corresponding to a sensitivity and specificity of 94% and 96%, respectively. Likewise, 46/51 samples were correctly defined as positive and 50/51 as negative for the presence of IgG anti-β2-GPI corresponding to a sensitivity and specificity of 90% and 98%, respectively. A wide variability in results pertaining to the positive samples was found for aCL-ELISA (coefficient of variation of 79%, 59%, and 53% for samples A, B, and C, respectively) as well as for aβ2-GPI-ELISA (coefficient of variation of 85%, 95%, and 50% for samples A, B, and C, respectively). This was confirmed when the analysis was restricted to those centres using the same commercial kit. Median antibody concentrations reported by centres for positive samples were consistent with the prolongation of coagulation tests assessing lupus anticoagulant (LA). Among these, dRVVT showed a good sensitivity and linear correlation with aCL antibody concentration. In conclusion, on the whole this survey found correct interpretation of positive and negative samples by both ELISAs. Nonetheless the high variability of reported data remains a major problem that only a consensus on the part of laboratories and manufacturers to utilize standard, uniform materials and procedures can hope to overcome
Self-testing and self-monitoring of oral anticoagulant therapy: consensus of the Italian Federation of Anticoagulation Clinics
Going Beyond Counting First Authors in Author Co-citation Analysis
The present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
False-negative or false-positive: laboratory diagnosis of lupus anticoagulant at the time of commencement of anticoagulant: a rebuttal
Variations on the Author
“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
We provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
- …
